Latest News

Purdue Pharma to distribute Helsinn’s CINV injection Aloxi in Canada

Canadian research-based pharmaceutical firm Purdue Pharma has entered a distribution and licence agreement to distribute, promote, market and sell Swiss pharmaceutical group Helsinn’s...

Purdue Pharma to distribute Helsinn’s CINV injection Aloxi in Canada

Veloxis Pharma signs agreements to commercialise Envarsus XR in China, Taiwan and Canada

Danish-based Veloxis Pharmaceuticals’ US subsidiary has signed two different exclusive licence, supply and distribution agreements to register, commercialise and distribute Envarsus XR in...

Veloxis Pharma signs agreements to commercialise Envarsus XR in China, Taiwan and Canada

FDA approves Sanofi and Regeneron’s Kevzara for adult rheumatoid arthritis

Sanofi and Regeneron Pharmaceuticals’ drug Kevzara (sarilumab) has received the US Food and Drug Administration (FDA) approval to treat adult patients affected with moderately to severely...

FDA approves Sanofi and Regeneron’s Kevzara for adult rheumatoid arthritis

Merck’s Isentress receives CHMP positive opinion to treat HIV-1 infection

Merck’s Isentress (raltegravir) 600mg film-coated tablets have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA),...

Merck’s Isentress receives CHMP positive opinion to treat HIV-1 infection

ST Asia signs licensing agreement with PharmaMar for anti-cancer compound lurbinectedin

Singapore-based biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will commercialise a new anti-cancer compound known as lurbinectedin (PM1183) throughout South East Asia,...

ST Asia signs licensing agreement with PharmaMar for anti-cancer compound lurbinectedin

Cytokinetics receives FDA orphan drug status for Ck-2127107 to treat SMA

Biopharmaceutical company Cytokinetics’ CK-2127107 has received orphan drug designation from the Office of Orphan Products Development of the US Food and Drug Administration (FDA) for the...

Cytokinetics receives FDA orphan drug status for Ck-2127107 to treat SMA

Vifor Pharma and Akebia to sell Vadadustat to Fresenius Medical Care

Vifor Pharma Group and Akebia Therapeutics have entered an exclusive licence agreement to sell Vadadustat to Fresenius Medical Care dialysis clinics located in the US after securing approval...

Vifor Pharma and Akebia to sell Vadadustat to Fresenius Medical Care

Manufacturers and contract packagers may miss serialisation deadlines, claims research

New industry research carried out by serialisation system provider SEA Vision and life science technology firm Zenith Technologies has claimed that nearly 36% of pharmaceutical manufacturers...

Manufacturers and contract packagers may miss serialisation deadlines, claims research

Pfizer’s 13-valent PCV selected in India’s immunisation programme

Pharmaceutical firm Pfizer’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) has been selected in India’s immunisation programme in selected...

Pfizer’s 13-valent PCV selected in India’s immunisation programme

Durect and Sandoz sign $293m deal to commercialise Posimir in US

Durect has signed a development and commercialisation agreement with Sandoz, a division of Novartis, to develop and market Posimir (Saber-Bupivacaine) in the...

Durect and Sandoz sign $293m deal to commercialise Posimir in US

Servier and miRagen extend research collaboration on microRNA-targeting therapeutics

Servier and miRagen Therapeutics have extended their research collaboration by adding microRNA-92 as a new therapeutic...

Servier and miRagen extend research collaboration on microRNA-targeting therapeutics

Atlantic Healthcare to submit NDA for Alicaforsen to treat pouchitis

Atlantic Healthcare has initiated the rolling submission of New Drug Application (NDA) with the US Food and Drug Administration (FDA) and filed its non-clinical data package for alicaforsen...

Atlantic Healthcare to submit NDA for Alicaforsen to treat pouchitis

Shire gains rights to develop and commercialise P-321 for ophthalmic indications

Shire has entered an agreement with Parion Sciences to gain exclusive worldwide rights to develop and commercialise P-321, an investigational epithelial sodium channel (ENaC) inhibitor...

Shire gains rights to develop and commercialise P-321 for ophthalmic indications

PIQUR Therapeutics’ PQR309 granted EMA Orphan Drug Designation for DLBCL

PIQUR Therapeutics’ PQR309 granted EMA Orphan Drug Designation for DLBCL

Shire’s Natpar receives EC conditional marketing authorisation for chronic hypoparathyroidism

Shire has received conditional marketing authorisation from the European Commission (EC) for Natpar (rhPTH / 1-84), a recombinant human protein with the full-length, 84-amino acid sequence...

Shire’s Natpar receives EC conditional marketing authorisation for chronic hypoparathyroidism

Servier and CTI BioPharma to expand collaboration to commericalise Pixuvri

Servier and CTI BioPharma have agreed to expand their existing licence and development collaboration agreement for Pixuvri...

Servier and CTI BioPharma to expand collaboration to commericalise Pixuvri

NICE recommends Ixekizumab (Taltz) to treat severe plaque psoriasis

Eli Lilly and Company has announced that UK NICE has recommended the usage of Ixekizumab (Taltz) as an option to treat adult patients suffering from severe plaque psoriasis who have...

NICE recommends Ixekizumab (Taltz) to treat severe plaque psoriasis

Novartis and Amgen expand global collaboration to commercialise AMG 334

Novartis has entered an expanded commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of...

Novartis and Amgen expand global collaboration to commercialise AMG 334

Paratek and Zai Lab sign deal to commercialise omadacycline in China

Paratek Pharmaceuticals has entered a collaboration with Chinese biopharmaceutical company Zai Lab (Shanghai) to support the development and commercialisation of omadacycline in...

Paratek and Zai Lab sign deal to commercialise omadacycline in China

Sanofi and Regeneron’s Kevzara receives CHMP opinion to treat Rheumatoid Arthritis

Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to...

Sanofi and Regeneron’s Kevzara receives CHMP opinion to treat Rheumatoid Arthritis

MPP signs licence and technology transfer agreement with Pharco Pharmaceuticals for RAV

MPP signs licence and technology transfer agreement with Pharco Pharmaceuticals for RAV
cachename:Newscachekey:rd-137342983_1380709040_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_526375455